Nu00c3u00obaria Eritja

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8201488/publications.pdf

Version: 2024-02-01

33	905	430874 18	477307 29
papers	citations	h-index	g-index

33	33	33	1866
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Autophagy in the physiological endometrium and cancer. Autophagy, 2021, 17, 1077-1095.	9.1	100
2	Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma. Modern Pathology, 2008, 21, 691-699.	5.5	71
3	Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. Autophagy, 2017, 13, 608-624.	9.1	65
4	Endometrial Carcinoma: Specific Targeted Pathways. Advances in Experimental Medicine and Biology, 2017, 943, 149-207.	1.6	53
5	Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. Anti-Cancer Drugs, 2008, 19, 115-124.	1.4	51
6	A Novel Three-Dimensional Culture System of Polarized Epithelial Cells to Study Endometrial Carcinogenesis. American Journal of Pathology, 2010, 176, 2722-2731.	3.8	46
7	CK2Î² Is Expressed in Endometrial Carcinoma and Has a Role in Apoptosis Resistance and Cell Proliferation. American Journal of Pathology, 2009, 174, 287-296.	3.8	42
8	An inducible knock-out mouse to model cell-autonomous role of PTEN in initiating endometrial, prostate and thyroid neoplasias. DMM Disease Models and Mechanisms, 2013, 6, 710-20.	2.4	38
9	Nuclear factor-ÎºB2/p100 promotes endometrial carcinoma cell survival under hypoxia in a HIF-1Î± independent manner. Laboratory Investigation, 2011, 91, 859-871.	3.7	33
10	KSR1 Is Overexpressed in Endometrial Carcinoma and Regulates Proliferation and TRAIL-Induced Apoptosis by Modulating FLIP Levels. American Journal of Pathology, 2011, 178, 1529-1543.	3.8	30
11	ETV5 transcription program links BDNF and promotion of EMT at invasive front of endometrial carcinomas. Carcinogenesis, 2014, 35, 2679-2686.	2.8	30
12	Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer. Gynecologic Oncology, 2019, 153, 425-435.	1.4	30
13	Tumor Heterogeneity in Endometrial Carcinoma: Practical Consequences. Pathobiology, 2018, 85, 35-40.	3.8	26
14	Nuclear factorâ€“ÎºB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma. Human Pathology, 2008, 39, 994-1001.	2.0	25
15	Palbociclib has antitumour effects on Ptenâ€deficient endometrial neoplasias. Journal of Pathology, 2017, 242, 152-164.	4.5	25
16	A Smad3-PTEN regulatory loop controls proliferation and apoptotic responses to TGF-Î² in mouse endometrium. Cell Death and Differentiation, 2017, 24, 1443-1458.	11.2	24
17	Long-Term Estradiol Exposure Is a Direct Mitogen for Insulin/EGF-Primed Endometrial Cells and Drives PTEN Loss-Induced Hyperplasic Growth. American Journal of Pathology, 2013, 183, 277-287.	3.8	22
18	Loss of Heterozygosity in Endometrial Carcinoma. International Journal of Gynecological Pathology, 2008, 27, 305-317.	1.4	18

#	Article	IF	Citations
19	Targeted sequencing with a customized panel to assess histological typing in endometrial carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 585-598.	2.8	17
20	T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAFV600E Melanoma. Journal of Investigative Dermatology, 2020, 140, 1253-1265.	0.7	17
21	Metabotyping human endometrioid endometrial adenocarcinoma reveals an implication of endocannabinoid metabolism. Oncotarget, 2016, 7, 52364-52374.	1.8	17
22	Combination of Vorinostat and caspaseâ€8 inhibition exhibits high antiâ€tumoral activity on endometrial cancer cells. Molecular Oncology, 2013, 7, 763-775.	4.6	16
23	Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias. European Journal of Cancer, 2016, 63, 74-87.	2.8	13
24	Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells. Molecular Cancer Therapeutics, 2014, 13, 776-787.	4.1	12
25	Modeling glands with PTEN deficient cells and microscopic methods for assessing PTEN loss: Endometrial cancer as a model. Methods, 2015, 77-78, 31-40.	3.8	12
26	Tumour-microenvironmental blood flow determines a metabolomic signature identifying lysophospholipids and resolvin D as biomarkers in endometrial cancer patients. Oncotarget, 2017, 8, 109018-109026.	1.8	12
27	Small-Molecule Inhibitors (SMIs) as an Effective Therapeutic Strategy for Endometrial Cancer. Cancers, 2020, 12, 2751.	3.7	12
28	ERÎ±-mediated repression of pro-inflammatory cytokine expression by glucocorticoids reveals a critical role for TNFÎ± and IL1Î± in lumen formation and maintenance.. Journal of Cell Science, 2012, 125, 1929-44.	2.0	11
29	Three-dimensional epithelial cultures: a tool to model cancer development and progression. Histology and Histopathology, 2013, 28, 1245-56.	0.7	10
30	ARID1Aâ€deficient cells require HDAC6 for progression of endometrial carcinoma. Molecular Oncology, 2022, 16, 2235-2259.	4.6	9
31	Deletion of Pten in CD45-expressing cells leads to development of T-cell lymphoblastic lymphoma but not myeloid malignancies. Blood, 2016, 127, 1907-1911.	1.4	7
32	Oral intake of genetically engineered high-carotenoid corn ameliorates hepatomegaly and hepatic steatosis in PTEN haploinsufficient mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 526-535.	3.8	6
33	Tumor suppressive function of E2Fâ€1 on PTENâ€induced serrated colorectal carcinogenesis. Journal of Pathology, 2019, 247, 72-85.	4.5	5